Literature DB >> 2296628

Biliary excretion of reduced haloperidol glucuronide.

N D Eddington1, D Young.   

Abstract

The biliary excretion of haloperidol and reduced haloperidol were investigated in the guinea pig. Bile duct cannulated guinea pigs were administered a single intraperitoneal dose of haloperidol (1 mg/kg). Bile was continually collected over a 12-h period. Aliquots of the bile samples were analyzed by HPLC for free haloperidol and reduced haloperidol. The remaining portions of the bile samples were incubated with beta glucuronidase and reanalyzed for haloperidol and reduced haloperidol. Although no significant amount of haloperidol glucuronide was detected in the bile, a new metabolite of reduced haloperidol, reduced haloperidol glucuronide, was found. The amount of reduced haloperidol excreted in the bile as the glucuronide conjugate was significantly higher than the amount of haloperidol or reduced haloperidol. These results imply that reduced haloperidol glucuronide may play a role in the disposition of haloperidol and/or its metabolite, reduced haloperidol.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2296628     DOI: 10.1007/bf02245788

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  10 in total

1.  Sensitive electrochemical high-performance liquid chromatography assay for the simultaneous determination of haloperidol and reduced haloperidol.

Authors:  N D Eddington; D Young
Journal:  J Pharm Sci       Date:  1988-06       Impact factor: 3.534

2.  Plasma haloperidol and clinical response: a role for reduced haloperidol in antipsychotic activity?

Authors:  M Shostak; J M Perel; R L Stiller; W Wyman; S Curran
Journal:  J Clin Psychopharmacol       Date:  1987-12       Impact factor: 3.153

3.  Interconversion between haloperidol and reduced haloperidol in humans.

Authors:  K K Midha; E M Hawes; J W Hubbard; E D Korchinski; G McKay
Journal:  J Clin Psychopharmacol       Date:  1987-10       Impact factor: 3.153

4.  Haloperidol metabolism and antipsychotic effect in schizophrenia.

Authors:  A C Altamura; M C Mauri; R Cavallaro; A Gorni
Journal:  Lancet       Date:  1987-04-04       Impact factor: 79.321

5.  Pharmacokinetic studies on haloperidol in man.

Authors:  A Forsman; R Ohman
Journal:  Curr Ther Res Clin Exp       Date:  1976-09

6.  Distribution excretion and metabolism of neuroleptics of the butyrophenone type. II. Distribution, excretion and metabolism of haloperidol in Sprague-Dawley rats.

Authors:  G A Braun; G I Poos; W Soudijn
Journal:  Eur J Pharmacol       Date:  1967-01       Impact factor: 4.432

7.  Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.

Authors:  L Ereshefsky; C M Davis; C A Harrington; M W Jann; J L Browning; S R Saklad; N R Burch
Journal:  J Clin Psychopharmacol       Date:  1984-06       Impact factor: 3.153

8.  Rapid formation of reduced haloperidol in guinea pigs following haloperidol administration.

Authors:  E R Korpi; D T Costakos; R J Wyatt
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1985-02

9.  Disposition and metabolism of [14C]-haloperidol in rats.

Authors:  H Miyazaki; Y Matsunaga; K Nambu; Y Oh-e; K Yoshida; M Hashimoto
Journal:  Arzneimittelforschung       Date:  1986-03

10.  Reduced haloperidol: effects on striatal dopamine metabolism and conversion to haloperidol in the rat.

Authors:  E R Korpi; R J Wyatt
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

  10 in total
  4 in total

1.  Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.

Authors:  W H Chang; Y W Lam; M W Jann; H Chen
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?

Authors:  W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice.

Authors:  James J Crowley; Yunjung Kim; Jin Peng Szatkiewicz; Amanda L Pratt; Corey R Quackenbush; Daniel E Adkins; Edwin van den Oord; Molly A Bogue; Hyuna Yang; Wei Wang; David W Threadgill; Fernando Pardo-Manuel de Villena; Howard L McLeod; Patrick F Sullivan
Journal:  Mamm Genome       Date:  2011-12-30       Impact factor: 2.957

4.  Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms.

Authors:  D W Eyles; T J Stedman; S M Pond
Journal:  Psychopharmacology (Berl)       Date:  1994-10       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.